Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/29281
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Karapetis C.S. | en |
dc.contributor.author | Price T.J. | en |
dc.contributor.author | Segelov E. | en |
dc.contributor.author | Tebbutt N.C. | en |
dc.contributor.author | Lau D.K. | en |
dc.contributor.author | Burge M. | en |
dc.contributor.author | Roy A. | en |
dc.contributor.author | Chau I. | en |
dc.contributor.author | Haller D.G. | en |
dc.contributor.author | Shapiro J.D. | en |
dc.contributor.author | Peeters M. | en |
dc.contributor.author | Pavlakis N. | en |
dc.date.accessioned | 2021-05-14T09:53:24Z | en |
dc.date.available | 2021-05-14T09:53:24Z | en |
dc.date.copyright | 2020 | en |
dc.date.created | 20200502 | en |
dc.date.issued | 2020-05-02 | en |
dc.identifier.citation | Expert Review of Anticancer Therapy. 20 (4) (pp 251-270), 2020. Date of Publication: 02 Apr 2020. | en |
dc.identifier.issn | 1473-7140 | en |
dc.identifier.uri | https://repository.monashhealth.org/monashhealthjspui/handle/1/29281 | en |
dc.description.abstract | Introduction: Outcomes in metastatic colorectal cancer are improving, due to the tailoring of therapy enabled by better understanding of clinical behavior according to molecular subtype. Areas covered: A review of the literature and recent conference presentations was undertaken on the topic of systemic treatment of metastatic colorectal cancer. This review summarizes expert discussion of the current evidence for therapies in metastatic colorectal cancer (mCRC) based on molecular subgrouping. Expert opinion: EGFR-targeted and VEGF-targeted antibodies are now routinely incorporated into treatment strategies for mCRC. EGFR-targeted antibodies are restricted to patients with extended RAS wild-type profiles, with evidence that they should be further restricted to patients with left-sided tumors. Clinically distinct treatment pathways based on tumor RAS, BRAF, HER2 and MMR status, are now clinically applicable. Evidence suggests therapy for additional subgroups will soon be defined; the most advanced being for patients with KRAS G12 C mutation and gene TRK fusion defects.Copyright © 2020, © 2020 Informa UK Limited, trading as Taylor & Francis Group. | en |
dc.language | en | en |
dc.language | English | en |
dc.publisher | Taylor and Francis Ltd | en |
dc.relation.ispartof | Expert Review of Anticancer Therapy | en |
dc.subject.mesh | encorafenib | - |
dc.subject.mesh | erlotinib | - |
dc.subject.mesh | fluoropyrimidine | - |
dc.subject.mesh | fluorouracil | - |
dc.subject.mesh | folinic acid | - |
dc.subject.mesh | gimeracil plus oteracil potassium plus tegafur | - |
dc.subject.mesh | irinotecan | - |
dc.subject.mesh | mitomycin | - |
dc.subject.mesh | oxaliplatin | - |
dc.subject.mesh | panitumumab | - |
dc.subject.mesh | ramucirumab | - |
dc.subject.mesh | tipiracil plus trifluridine | - |
dc.subject.mesh | trametinib | - |
dc.subject.mesh | BRAF gene | - |
dc.subject.mesh | HER2 gene | - |
dc.subject.mesh | KRAS gene | - |
dc.subject.mesh | NTRK gene | - |
dc.subject.mesh | mrtx 849 | - |
dc.subject.mesh | vemurafenib | - |
dc.subject.mesh | cancer chemotherapy | - |
dc.subject.mesh | diarrhea | - |
dc.subject.mesh | evidence based medicine | - |
dc.subject.mesh | febrile neutropenia | - |
dc.subject.mesh | gene | - |
dc.subject.mesh | gene amplification | - |
dc.subject.mesh | gene expression | - |
dc.subject.mesh | gene mutation | - |
dc.subject.mesh | medical expert | - |
dc.subject.mesh | medical specialist | - |
dc.subject.mesh | metastatic colorectal cancer | - |
dc.subject.mesh | microbiome | - |
dc.subject.mesh | mismatch repair | - |
dc.subject.mesh | neutropenia | - |
dc.subject.mesh | signal transduction | - |
dc.subject.mesh | aflibercept | - |
dc.subject.mesh | bevacizumab | - |
dc.subject.mesh | capecitabine | - |
dc.subject.mesh | cetuximab | - |
dc.subject.mesh | circulating tumor DNA | - |
dc.subject.mesh | dabrafenib | - |
dc.title | Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019. | en |
dc.type | Review | en |
dc.identifier.affiliation | Oncology | - |
dc.type.studyortrial | Review article (e.g. literature review, narrative review) | - |
dc.identifier.doi | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1080/14737140.2020.1744439 | - |
dc.publisher.place | United Kingdom | en |
dc.identifier.pubmedid | 32186929 [http://www.ncbi.nlm.nih.gov/pubmed/?term=32186929] | en |
dc.identifier.source | 2004594345 | en |
dc.identifier.institution | (Lau, Chau) GI and Lymphoma Unit, Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom (Burge) Medical Oncology, Royal Brisbane Hospital, Brisbane, Australia (Burge) University of Queensland, Brisbane, Australia (Roy) Medical Oncology, Flinders Centre for Innovation in Cancer, Bedford Park, Australia (Haller) Abramson Cancer Center at the Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States (Shapiro, Segelov) Monash University, Melbourne, Australia (Shapiro) Medical Oncology, Cabrini Medical Centre, Melbourne, Australia (Peeters) Medical Oncology, University Hospital Antwerp, Edegem, Belgium (Pavlakis) Medical Oncology, Royal North Shore Hospital, St Leonards, Australia (Pavlakis) Sydney University, Camperdown, Sydney, Australia (Karapetis) Medical Oncology, Flinders Medical Centre, Bedford Park, Australia (Tebbutt) Medical Oncology, Austin Health, Heidelberg, Australia (Tebbutt) Department of Surgery, University of Melbourne, Melbourne, Australia (Segelov) Medical Oncology, Monash Medical Centre, Clayton, Australia (Price) Medical Oncology, The Queen Elizabeth Hospital, Woodville, Australia | en |
dc.description.address | T.J. Price, Medical Oncology, The Queen Elizabeth Hospital, Woodville, Australia. E-mail: timothy.price@health.sa.gov.au | en |
dc.description.publicationstatus | Embase | en |
dc.rights.statement | Copyright 2020 Elsevier B.V., All rights reserved. | en |
dc.subect.keywords | BRAF chemotherapy Colorectal consensus metastatic MSI RAS | en |
dc.identifier.authoremail | Price T.J.; timothy.price@health.sa.gov.au | en |
dc.description.grant | Organization: *Beijing Institute of Technology Research Fund Program for Young Scholars* Organization No: 501100012236 Country: China | en |
item.fulltext | No Fulltext | - |
item.openairetype | Review | - |
item.grantfulltext | none | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Oncology | - |
Appears in Collections: | Articles |
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.